Comparison of Two Strategies for the Delivery of IPTc
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Antimalarial chemoprophylaxis can reduce morbidity and mortality from malaria in children. However, this approach to malaria control has not been implemented widely because of concerns over its possible effect on the development of resistance and natural immunity. Intermittent preventive treatment (IPT) may be able to achieve some of the beneficial effects of chemoprophylaxis without its drawbacks. Recently, it has been shown that IPT given to Senegalese children under the age of five years on three occasions during the malaria transmission season reduced the incidence of clinical malaria by approximately 90%. However, it is uncertain how this intervention can be most effectively delivered. Therefore, 26 Maternal and Child Health (MCH) trekking clinics in Upper River Division, south of the River Gambia, each with an average catchment population of 400-500 children under 5 years of age, will be randomly allocated to receive IPT from the MCH trekking team or from a IPT dispenser (village health worker, traditional birth attendant or a community mother based in a primary health care village). Treatment with a single dose of sulfadoxine /pyrimethamine (SP) plus three doses of amodiaquine will be given to all study subjects at monthly intervals on three occasions during the months of September, October and November. The primary end points will be the incidence of clinical attacks of malaria detected by passive case detection, and cost-effectiveness of the delivery methods. Important secondary endpoints will be the coverage and the equity of coverage of IPT in preventing malaria morbidity.
| Condition | Intervention | Phase |
|---|---|---|
|
Malaria |
Drug: sulfadoxine /pyrimethamine plus amodiaquine |
Phase 4 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Prevention |
| Official Title: | Comparison of Two Strategies for the Delivery of Intermittent Preventive Treatment in Children (IPTc) in an Area of Seasonal Malaria Transmission |
- Malaria incidence (the number of OPD attendances with clinical malaria that meet the case definitions as indicated below during the surveillance period ) and the number of hospital admissions with malaria during the surveillance period. [ Time Frame: during malaria transmission period ]
- Cost-effectiveness of the delivery system. [ Time Frame: during the study period ]
- Coverage of IPTC [ Time Frame: During the study period ]
- the proportion of children who received three IPT courses on schedule; [ Time Frame: during the study period ]
- the proportion of children who received partial or off-schedule IPT courses [ Time Frame: during the study period ]
- the proportion of children with no IPT. [ Time Frame: during the study period ]
- Unit cost of delivery per fully adherent child. [ Time Frame: during the study period ]
- Incremental cost-effectiveness ratio for each systems of delivery. [ Time Frame: During the study period ]
- Mean Hb (g/dl) [ Time Frame: at the end of malaria transmission ]
- Prevalence of malaria parasitaemia [ Time Frame: At the end of the malaria transmission season ]
| Enrollment: | 14000 |
| Study Start Date: | May 2006 |
| Study Completion Date: | February 2007 |
Show Detailed Description
Eligibility| Ages Eligible for Study: | 3 Months to 5 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Age between 3 months and 5 years at enrolment.
- Informed consent obtained from parents or legal guardians.
- No current participation in another malaria intervention trial.
Exclusion Criteria:
1. Previous adverse reaction to treatment with SP or amodiaquine. If this is unknown, then a history of allergic reaction to any drug.
Contacts and Locations| Gambia | |
| MRC Laboratories | |
| Banjul, Gambia, PO Box 273 | |
| Principal Investigator: | Kalifa Bojang, MD | MRC Laboratories, The Gambia |
More Information
No publications provided by Gates Malaria Partnership
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| ClinicalTrials.gov Identifier: | NCT00376155 History of Changes |
| Other Study ID Numbers: | ITCRVG47, SCC990 |
| Study First Received: | September 13, 2006 |
| Last Updated: | February 7, 2008 |
| Health Authority: | Gambia: MRC Ethics Committee |
Keywords provided by Gates Malaria Partnership:
|
malaria prevention intermittent drugs |
Additional relevant MeSH terms:
|
Malaria Protozoan Infections Parasitic Diseases Amodiaquine Pyrimethamine Sulfadoxine Antimalarials Antiprotozoal Agents Antiparasitic Agents |
Anti-Infective Agents Therapeutic Uses Pharmacologic Actions Folic Acid Antagonists Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Anti-Infective Agents, Urinary Renal Agents |
ClinicalTrials.gov processed this record on May 16, 2013